ClinicalTrials.gg
Not yet recruitingNCT01876355CATAPRESUpdated Feb 15, 2023

The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients

A Phase 3 interventional study of Clonidine and SodiumChloride in Delirium, sponsored by Deventer Ziekenhuis. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-02-15.

Sponsored by Deventer Ziekenhuis · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 31 studies in Delirium with a site in Netherlands — 3 open to participants now, 3 under way, 1 of them phase 3. Delirium · Netherlands.

Planned enrollment
13th of 18
115 · median 174
Started
2024
with 1 other
Phase 3
5 of 31
1 open now
Registered
13th of 31
by date
Lead sponsor
2 of 31
Deventer Ziekenhuis

Among the 31 studies in Delirium with a site in Netherlands, this one is the 13th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2024, is one of 5 in phase 3, and was the 13th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

3 of the 31 studies in Delirium with a site in Netherlands are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Delirium with a site in Netherlands, or all of them as a file.
02

Study summary

Rationale: Delirium is highly prevalent in the ICU. GABA-ergic anaesthetics may provoke delirium. Alpha-2-adrenergic agonists may lead to a reduction of the total amount of GABA-ergic anaesthetics and reduction of delirium. There are no large studies proving that this therapy is effective and safe.

Objective: The objective of this study is to compare the effect of clonidine with placebo on the occurrence and duration of delirium in mechanically ventilated ICU patients.

Study design: Prospective randomised double-blind placebo controlled intervention study in 115 patients.

Study population: All patients >18 years old, intubated mechanically ventilated and sedated at inclusion.

Intervention: Clonidine infusion of 0,25 mcg/kg/h added to the standard sedation regimen. Comparison: NaCl 0,9 % infusion as placebo.

Main study parameters/endpoints: The main study parameter is the total number of awake and delirium-free observation periods the first 7 days after randomisation. An observation period is a nursing shift of 8 hours.

Read the detailed description

Rationale: Delirium is highly prevalent in the ICU. It may cause significant morbidity and mortality. One of the factors that may provoke a delirium is the use of GABA-ergic anaesthetics. Recent studies have shown that sedation with alpha-2-adrenergic agonists may lead to a reduction of the total amount of GABA-ergic anaesthetics and reduction of delirium. In clinical practice the alpha-2-adrenergic agent clonidine is used as an add-on sedative in mechanically ventilated patients who suffer from delirium, but there are no large studies proving that this therapy is effective and safe.

Objective: The objective of this study is to compare the effect of clonidine with placebo on the occurrence and duration of delirium in mechanically ventilated ICU patients.

Study design: Prospective randomised double-blind placebo controlled intervention study in 115 patients.

Study population: All patients >18 years old, intubated mechanically ventilated and sedated at inclusion.

Intervention: Clonidine infusion of 0,25 mcg/kg/h added to the standard sedation regimen. Comparison: NaCl 0,9 % infusion as placebo.

Main study parameters/endpoints: The main study parameter is the total number of awake and delirium-free observation periods the first 7 days after randomisation. An observation period is a nursing shift of 8 hours.. A delirium-free period is a shift in which the CAM-ICU score is negative.

Secondary endpoints: RASS sedation score, total number of delirium positive observation periods, total amount of sedatives, analgesics and antipsychotics used, organ failure score, ventilation and sedation free days at day 30, mortality.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden associated with participation is minimal. All blood samples, CAM-ICU scores and physical examinations required for the study are routine daily practice on the ICU. Adding clonidine for sedation of critically ill patients is common practice in many ICU's in the Netherlands.. Its use is also suggested in the NVIC guideline delirium on the ICU. It is however an off-label treatment. The major side effects of the study medication clonidine are hypertension, hypotension and bradycardia. Smaller studies have shown that these side effects are comparable to midazolam. Hypotension is a phenomenon that occurs very often in ICU patients, and is caused by different conditions, not only by the use of sedative medication. The benefit of participation is the possibility to reduce the period of delirium during ICU stay. Because of the widely off label use of clonidine in sedated and ventilated critically ill ICU patients this study is relevant to test the hypothesis that sedation with clonidine leads to a lower incidence and shorter duration of delirium.

03

Conditions studied

  • Delirium

Browse trials for

Keywords

  • Delirium, clonidine, ICU, sedation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Intubated and mechanically ventilated, at the start of the study medication.
  • Age > 18 years

Exclusion criteria

Exclusion Criteria:

  • Severe neurotrauma/CVA
  • Severe dementia
  • Inability to speak Dutch or English
  • The use of clonidine during the 96 hours before the start of the study.
  • Bradycardia (\<50/min)
  • Severe hypotension (MAP \< 65 after volume resuscitation and two vasopressors)
  • Pregnancy
  • Epilepsy
  • Known clonidine intolerance
  • Liver cirrhosis ( Class C)
  • Recent and acute myocardial infarction
  • Severe heart failure (\<30%)
  • Second or third degree AV block
  • Renal insufficiency requiring intermittent haemodialysis (CVVH is permitted)
  • Expected transfer to another hospital
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (estimated)

Study arms

  • Experimental
    Clonidine

    Drug: Clonidine

  • Placebo comparator
    Sodium chloride

    Drug: SodiumChloride

Interventions

  • o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.

    Also known as: Catapressan

  • DrugSodiumChloride

    Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. CAM-ICU (Confusion Assessment Method for the Intesive Care Unit)

    The total amount of delirium-free periods during 7 days after randomisation and start of the study medication. An observation period is a period of 8 hours, coinciding with one nursing shift. A delirium-free period is a shift in which the delirium score is negative.

    Time frame: 7 days

Secondary outcomes

  1. Signs of agitation

    Signs of agitation (for example self removed catheter).

    Time frame: 7 days

  2. Opiate use

    Time frame: 7 days

  3. Sedative use

    Time frame: 7 days

  4. Anti-psychotic use

    Time frame: 7 days

  5. Ventilation free days

    Time frame: 7 days

  6. Sedation free days

    Time frame: 7 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2024; primary completion for Dec 2024, 11 months later.

Of 27 phase 3 interventional studies under Delirium, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 59. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2013
First posted
Jun 12, 2013
StartEst.
Jan 2024
Primary completionEst.
Dec 2024
CompletionEst.
Jun 2025
Last update
Feb 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01876355
Lead sponsor
Deventer Ziekenhuis
Responsible party
Marieke Zeeman (Principal Investigator, Deventer Ziekenhuis) — Principal investigator
First posted
Jun 12, 2013
Start date
Jan 2024 (estimated)
Primary completion
Dec 2024 (estimated)
Completion
Jun 2025 (estimated)
Last update
Feb 15, 2023

Study contacts

M. Zeeman
Contact
M.Zeeman@dz.nl
+31570535045
H.L.A. van den Oever
Contact
OevervdH@dz.nl
+31570535353
H.L.A. van den Oever
principal investigator · Deventer Ziekenhuis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Clonidine

Start the discussion